166 related articles for article (PubMed ID: 38148376)
1. Low blood level of tumour suppressor miR-5193 as a target of immunotherapy to PD-L1 in gastric cancer.
Kamiya H; Komatsu S; Takashima Y; Ishida R; Arakawa H; Nishibeppu K; Kiuchi J; Imamura T; Ohashi T; Shimizu H; Arita T; Konishi H; Shiozaki A; Kubota T; Fujiwara H; Yagyu S; Iehara T; Otsuji E
Br J Cancer; 2024 Mar; 130(4):671-681. PubMed ID: 38148376
[TBL] [Abstract][Full Text] [Related]
2. HIF1A-AS2 Promotes the Proliferation and Metastasis of Gastric Cancer Cells Through miR-429/PD-L1 Axis.
Mu L; Wang Y; Su H; Lin Y; Sui W; Yu X; Lv Z
Dig Dis Sci; 2021 Dec; 66(12):4314-4325. PubMed ID: 33555514
[TBL] [Abstract][Full Text] [Related]
3. PD-L1
Li Q; Zhou ZW; Lu J; Luo H; Wang SN; Peng Y; Deng MS; Song GB; Wang JM; Wei X; Wang D; Westover KD; Xu CX
Mol Ther; 2022 Feb; 30(2):621-631. PubMed ID: 34547468
[TBL] [Abstract][Full Text] [Related]
4. miR-105-5p regulates PD-L1 expression and tumor immunogenicity in gastric cancer.
Miliotis C; Slack FJ
Cancer Lett; 2021 Oct; 518():115-126. PubMed ID: 34098061
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of DAPK1-mediated inhibition of IKKβ/CSN5/PD-L1 axis enhances natural killer cell killing ability and inhibits tumor immune evasion in gastric cancer.
Guo Z; Zhou C; Zhou L; Wang Z; Zhu X; Mu X
Cell Immunol; 2022 Feb; 372():104469. PubMed ID: 35114597
[TBL] [Abstract][Full Text] [Related]
6. Depletion of tumor suppressor miRNA-148a in plasma relates to tumor progression and poor outcomes in gastric cancer.
Komatsu S; Imamura T; Kiuchi J; Takashima Y; Kamiya H; Ohashi T; Konishi H; Shiozaki A; Kubota T; Okamoto K; Otsuji E
Am J Cancer Res; 2021; 11(12):6133-6146. PubMed ID: 35018247
[TBL] [Abstract][Full Text] [Related]
7. miR-142-5p regulates tumor cell PD-L1 expression and enhances anti-tumor immunity.
Jia L; Xi Q; Wang H; Zhang Z; Liu H; Cheng Y; Guo X; Zhang J; Zhang Q; Zhang L; Xue Z; Li Y; Da Y; Zhao P; Zhang R
Biochem Biophys Res Commun; 2017 Jun; 488(2):425-431. PubMed ID: 28511795
[TBL] [Abstract][Full Text] [Related]
8. MiR-195/-16 Family Enhances Radiotherapy via T Cell Activation in the Tumor Microenvironment by Blocking the PD-L1 Immune Checkpoint.
Tao Z; Xu S; Ruan H; Wang T; Song W; Qian L; Chen K
Cell Physiol Biochem; 2018; 48(2):801-814. PubMed ID: 30032144
[TBL] [Abstract][Full Text] [Related]
9. MiR-940 promotes the proliferation and migration of gastric cancer cells through up-regulation of programmed death ligand-1 expression.
Fan Y; Che X; Hou K; Zhang M; Wen T; Qu X; Liu Y
Exp Cell Res; 2018 Dec; 373(1-2):180-187. PubMed ID: 30367831
[TBL] [Abstract][Full Text] [Related]
10. Serum exosomal miR-16-5p functions as a tumor inhibitor and a new biomarker for PD-L1 inhibitor-dependent immunotherapy in lung adenocarcinoma by regulating PD-L1 expression.
Chen HL; Luo YP; Lin MW; Peng XX; Liu ML; Wang YC; Li SJ; Yang DH; Yang ZX
Cancer Med; 2022 Jul; 11(13):2627-2643. PubMed ID: 35347894
[TBL] [Abstract][Full Text] [Related]
11. Tumour-activated neutrophils in gastric cancer foster immune suppression and disease progression through GM-CSF-PD-L1 pathway.
Wang TT; Zhao YL; Peng LS; Chen N; Chen W; Lv YP; Mao FY; Zhang JY; Cheng P; Teng YS; Fu XL; Yu PW; Guo G; Luo P; Zhuang Y; Zou QM
Gut; 2017 Nov; 66(11):1900-1911. PubMed ID: 28274999
[TBL] [Abstract][Full Text] [Related]
12. miR-194-5p down-regulates tumor cell PD-L1 expression and promotes anti-tumor immunity in pancreatic cancer.
Wang C; Li X; Zhang L; Chen Y; Dong R; Zhang J; Zhao J; Guo X; Yang G; Li Y; Gu C; Xi Q; Zhang R
Int Immunopharmacol; 2021 Aug; 97():107822. PubMed ID: 34098485
[TBL] [Abstract][Full Text] [Related]
13. Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in
Peng XX; Yu R; Wu X; Wu SY; Pi C; Chen ZH; Zhang XC; Gao CY; Shao YW; Liu L; Wu YL; Zhou Q
J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31959728
[TBL] [Abstract][Full Text] [Related]
14. Low levels of tumour suppressor miR-655 in plasma contribute to lymphatic progression and poor outcomes in oesophageal squamous cell carcinoma.
Kiuchi J; Komatsu S; Imamura T; Nishibeppu K; Shoda K; Arita T; Kosuga T; Konishi H; Shiozaki A; Okamoto K; Fujiwara H; Ichikawa D; Otsuji E
Mol Cancer; 2019 Jan; 18(1):2. PubMed ID: 30609933
[TBL] [Abstract][Full Text] [Related]
15. The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer.
Zhao L; Yu H; Yi S; Peng X; Su P; Xiao Z; Liu R; Tang A; Li X; Liu F; Shen S
Oncotarget; 2016 Jul; 7(29):45370-45384. PubMed ID: 27248318
[TBL] [Abstract][Full Text] [Related]
16. Reactive oxygen species reprogram macrophages to suppress antitumor immune response through the exosomal miR-155-5p/PD-L1 pathway.
Li X; Wang S; Mu W; Barry J; Han A; Carpenter RL; Jiang BH; Peiper SC; Mahoney MG; Aplin AE; Ren H; He J
J Exp Clin Cancer Res; 2022 Jan; 41(1):41. PubMed ID: 35086548
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-124-3p suppresses PD-L1 expression and inhibits tumorigenesis of colorectal cancer cells via modulating STAT3 signaling.
Roshani Asl E; Rasmi Y; Baradaran B
J Cell Physiol; 2021 Oct; 236(10):7071-7087. PubMed ID: 33821473
[TBL] [Abstract][Full Text] [Related]
18. Increased intratumoral mast cells foster immune suppression and gastric cancer progression through TNF-α-PD-L1 pathway.
Lv Y; Zhao Y; Wang X; Chen N; Mao F; Teng Y; Wang T; Peng L; Zhang J; Cheng P; Liu Y; Kong H; Chen W; Hao C; Han B; Ma Q; Zou Q; Chen J; Zhuang Y
J Immunother Cancer; 2019 Feb; 7(1):54. PubMed ID: 30808413
[TBL] [Abstract][Full Text] [Related]
19. CircSCUBE3 Reduces the Anti-gastric Cancer Activity of Anti-PD-L1.
Shan H; Zhang X; Zhang X; Wei Y; Meng L; Li J; Zhang Z; Ma L; Xiao Y
Mol Biotechnol; 2024 Jan; 66(1):123-137. PubMed ID: 37052807
[TBL] [Abstract][Full Text] [Related]
20. Cancer-associated fibroblasts-derived exosomes promote lung cancer progression by OIP5-AS1/ miR-142-5p/ PD-L1 axis.
Jiang Y; Wang K; Lu X; Wang Y; Chen J
Mol Immunol; 2021 Dec; 140():47-58. PubMed ID: 34653794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
